

Non-Hospital Medical and Surgical
Facilities Accreditation Program

ACCREDITATION STANDARDS

Intravenous Use of Ketamine for the Treatment of Mood Disorders

Copyright © 2023 by the Non-Hospital Medical and Surgical Facilities Accreditation Program and the College of Physicians and Surgeons of British Columbia.

All rights reserved. No part of this publication may be used, reproduced or transmitted, in any form or by any means electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system or any nature, without the prior written permission of the copyright holder, application for which shall be made to:

Non-Hospital Medical and Surgical Facilities Accreditation Program
College of Physicians and Surgeons of British Columbia
300-669 Howe Street
Vancouver BC V6C 0B4

The Non-Hospital Medical and Surgical Facilities Accreditation Program and the College of Physicians and Surgeons of BC has used their best efforts in preparing this publication. As websites are constantly changing, some of the website addresses in this publication may have moved or no longer exist.

Introduction

Ketamine administration for the treatment of mood disorders such as major depressive disorder (MDD) by the intravenous (IV) route must be performed in an accredited non-hospital facility. This standard does not apply to intranasal esketamine (SPRAVATO®), intramuscular (IM), subcutaneous (SC), or oral (PO) ketamine administration in a non-accredited facility (e.g. physician office/clinic) which are addressed in the College's interim guidance _____.


Ketamine is a dissociative anesthetic agent capable of producing amnesia, analgesia and all degrees of sedation, including general anesthesia. Ketamine has the potential for serious side effects including tachyarrhythmias, hypertension, hallucinations and delirium.

No.	Description
KET1.0	INTRAVENOUS USE OF KETAMINE FOR THE TREATMENT OF MOOD DISORDERS
KET1.1	Pre-admission evaluation ensures all patients scheduled for treatment are appropriate for the non-hospital setting.

No.	Description
KET1.2.8	M The psychiatric management plan includes the clinical impression, treatment and follow-up plan including the rationale for treatment selection.
KET1.2.9	M The psychiatric management plan includes documentation of the consent discussion.

No.	Description
-----	-------------

No.	Description
KET1.6.4	M Anesthesiologists administering ketamine for the treatment of mood disorders at the facility have the requisite credentials for privileges as outlined in the Provincial Privileging Dictionaries.
KET1.6.5	M Each anesthesiologist that has not practiced anesthesia in a hospital setting within three years holds current ACLS training.
KET1.6.6	M The current and professional performance of each anesthesiologist is evaluated annually through performance review and renewal of appointment processes.



No.

No.	Description
KET1.8.2	M Each registered nurse holds current basic life support certification.

No.	Description
KET1.9.3	M There is a third regulated health

No.	Description
-----	-------------

No.	Description
KET1.11.5	M Level of consciousness and depth of sedation is monitored during treatment and the post-treatment monitoring phase.
KET1.11.6	M Blood pressure and respiratory rate are frequently assessed during treatment and post-treatment monitoring phase.
KET1.11.7	M

No.	Description
-----	-------------

References

BC College of Nurses and Midwives. Scope of practice for licensed practical nurses [Internet]. Vancouver, BC: BC College of Nurses and Midwives; 2020 Sep 24 [rev 2020 Nov 27; cited 2020 Oct 22].

Ministry of Health. Health care providers' guide to consent to health care [Internet]. Victoria (BC): Government of British Columbia; 2011 Jul [cited 2020 Oct 27].

Furrey K, Wilkins K. Prescribing 'off-label': what should a physician disclose? *AMA J Ethics* [Internet]. 2016 Jun [cited 2020 Oct 29];18(6):587-93.

College of Physicians and Surgeons of British Columbia. Practice standard: complementary and alternative therapies [Internet]. Vancouver: College of Physicians and Surgeons of British Columbia; 1999 [updated 2020 May 11; cited 2020 Oct 29]. 5 p.

College of Physicians and Surgeons of British Columbia [Internet]. Vancouver: College of Physicians and Surgeons of British Columbia; c2020. Clarification on college requirements for intranasal esketamine; 2020 Oct 22 [cited 2020 Oct 29].

U.S. Food and Drug Administration [Internet]. Silver Spring, MD: Government of the United States; c2020. Infusion pump risk reduction strategies for facility administrators and managers; 2018 Feb 2 [cited 2020 Nov 3].

U.S. Food and Drug Administration [Internet]. Silver Spring, MD: Government of the United States; c2020. Infusion pump risk reduction strategies for clinicians; 2018 Feb 2 [cited 2020 Nov 3].

U.S. Food and Drug Administration [Internet]. Silver Spring, MD: Government of the United States; c2020. Infusion pump risk reduction strategies for pharmacists; 2018 Feb 2 [cited 2020 Nov 3].

Sanacora G, Frye MA, McDonald W, Matthew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB. A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA Psychiatry* [Internet]. 2017 Apr 1 [cited 2020 Nov 4]; 74(4):399-405.

Sanacora G, Frye MA, McDonald W, Matthew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB. A consensus statement on the use of ketamine in the treatment of mood disorders: supplementary online content. *JAMA Psychiatry* [Internet]. 2017 Apr 1 [cited 2020 Nov 4].

NSpravato®: esketamine nasal spray [Internet]. 15th version. Toronto (ON) [Internet]. 2017 Oct 1 [cited 2020 Nov 4].

